{"id":"antipyrine","_fda":{"id":"2b9edb0e-49a1-f422-e063-6294a90ae8fa","set_id":"c9463aa1-ac37-42f9-bc2b-785e3d2befad","openfda":{"nui":["N0000185375","N0000175629","N0000184306","N0000185001","M0000728","M0016962","M0516536"],"unii":["T3CHA1B51H","O80TY208ZW","6P669D8HQ8","H19J064BA5","O3B55K4YKI","00543AP1JV","XK4IUX8MNB","E1UOL152H7","G0R4UBI2ZZ","W2469WNO6U","QDL83WN8C2","WYT05213GE","269XH13919","QNS6W5US1Z"],"route":["SUBLINGUAL"],"spl_id":["2b9edb0e-49a1-f422-e063-6294a90ae8fa"],"brand_name":["D-119"],"spl_set_id":["c9463aa1-ac37-42f9-bc2b-785e3d2befad"],"package_ndc":["58264-0125-1"],"product_ndc":["58264-0125"],"generic_name":["PLANTAGO MAJOR, DELPHINIUM STAPHISAGRIA SEED, MATRICARIA CHAMOMILLA, SEPIA OFFICINALIS JUICE, ARNICA MONTANA, HYPERICUM PERFORATUM, STRYCHNOS NUX-VOMICA SEED, SPIGELIA ANTHELMIA, IRON, BARIUM CARBONATE, VERATRUM ALBUM ROOT, CALCIUM FLUORIDE, ANTIPYRINE, AND BISMUTH SUBNITRATE"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]","Plant Proteins [CS]","Seed Storage Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]","Increased IgG Production [PE]"],"substance_name":["ANTIPYRINE","ARNICA MONTANA","BARIUM CARBONATE","BISMUTH SUBNITRATE","CALCIUM FLUORIDE","DELPHINIUM STAPHISAGRIA SEED","HYPERICUM PERFORATUM","IRON","MATRICARIA CHAMOMILLA","PLANTAGO MAJOR","SEPIA OFFICINALIS JUICE","SPIGELIA ANTHELMIA","STRYCHNOS NUX-VOMICA SEED","VERATRUM ALBUM ROOT"],"pharm_class_epc":["Non-Standardized Plant Allergenic Extract [EPC]"],"manufacturer_name":["DNA Labs, Inc."],"is_original_packager":[true]},"purpose":["Toothaches, swollen gums, jaw pain."],"version":"3","warnings":["Warnings Use only if cap seal is unbroken. If pregnant or breastfeeding, ask a healthcare professional before use. Keep this and all medication out of the reach of children."],"effective_time":"20250113","active_ingredient":["INGREDIENTS ACTIVE Plantago major 6x, 30x, Staphysagria 12x, 30x, Chamomilla vulgaris 30x, 200x, Sepia officinalis 6x, 30x, Arnica montana 6x, 30x, Hypericum perforatum 6x, 30x, Nux vomica 4x, 30x, Spigelia anthelmia 6x, 30x, Ferrum metallicum 8x, 30x, Baryta carbonica 8x, 30x, Veratrum album 6x, 30x, Calcarea fluorica 8x, 30x, Antipyrine 12x, Bismuthum 8x, 30x INACTIVE 20% alcohol in purified water."],"inactive_ingredient":["INACTIVE 20% alcohol in purified water."],"storage_and_handling":["SHAKE WELL"],"indications_and_usage":["INDICATIONS Toothaches, swollen gums, jaw pain."],"spl_unclassified_section":["NDC 58264-0125-1","To be used according to standard homeopathic indications."],"dosage_and_administration":["SUGGESTED DOSAGE One dropper under tongue two times daily. Acute symptoms ½ dropper under tongue every 30 minutes for two hours."],"spl_product_data_elements":["D-119 Plantago major, Delphinium staphisagria seed, Matricaria chamomilla, Sepia officinalis juice, Arnica montana, Hypericum perforatum, Strychnos nux-vomica seed, Spigelia anthelmia, Iron, Barium carbonate, Veratrum album root, Calcium fluoride, Antipyrine, and Bismuth subnitrate ALCOHOL WATER PLANTAGO MAJOR PLANTAGO MAJOR DELPHINIUM STAPHISAGRIA SEED DELPHINIUM STAPHISAGRIA SEED MATRICARIA CHAMOMILLA MATRICARIA CHAMOMILLA SEPIA OFFICINALIS JUICE SEPIA OFFICINALIS JUICE ARNICA MONTANA ARNICA MONTANA HYPERICUM PERFORATUM HYPERICUM PERFORATUM STRYCHNOS NUX-VOMICA SEED STRYCHNOS NUX-VOMICA SEED SPIGELIA ANTHELMIA SPIGELIA ANTHELMIA IRON IRON BARIUM CARBONATE BARIUM CATION VERATRUM ALBUM ROOT VERATRUM ALBUM ROOT CALCIUM FLUORIDE FLUORIDE ION ANTIPYRINE ANTIPYRINE BISMUTH SUBNITRATE BISMUTH CATION"],"pregnancy_or_breast_feeding":["If pregnant or breastfeeding, ask a healthcare professional before use."],"keep_out_of_reach_of_children":["Keep this and all medication out of the reach of children."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1 FL. OZ. Bottle Label DYNAMIC NUTRITIONAL ASSOCIATES, INC. D 119 HOMEOPATHIC STRESS FORMULA 1 FL. OZ. PRINCIPAL DISPLAY PANEL - 1 FL. OZ. Bottle Label"]},"safety":{"boxedWarnings":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ANTIPYRINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:51:02.465673+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:51:09.362711+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ANTIPYRINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:51:10.238990+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:51:00.330971+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:51:00.331027+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:51:19.684133+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:51:00.331042+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cyclooxygenase-1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:51:10.841697+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL277474/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:51:10.721471+00:00"}},"_dailymed":{"setId":"c9463aa1-ac37-42f9-bc2b-785e3d2befad","title":"D-119 (PLANTAGO MAJOR, DELPHINIUM STAPHISAGRIA SEED, MATRICARIA CHAMOMILLA, SEPIA OFFICINALIS JUICE, ARNICA MONTANA, HYPERICUM PERFORATUM, STRYCHNOS NUX-VOMICA SEED, SPIGELIA ANTHELMIA, IRON, BARIUM CARBONATE, VERATRUM ALBUM ROOT, CALCIUM FLUORIDE, ANTIPYRINE, AND BISMUTH SUBNITRATE) SOLUTION [DNA LABS, INC.]"},"mechanism":{"drugClass":"Non-Standardized Plant Allergenic Extract [EPC]"},"_scrapedAt":"2026-03-28T00:44:39.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:51:19.949806+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"antipyrine-toothaches","name":"Toothaches","dosing":null,"approvals":[],"diseaseId":"","eligibility":null,"pivotalTrial":null,"restrictions":[],"patientPopulation":null,"diagnosticRequired":null,"brandNameForIndication":""},{"id":"antipyrine-swollen-gums","name":"Swollen Gums","dosing":null,"approvals":[],"diseaseId":"","eligibility":null,"pivotalTrial":null,"restrictions":[],"patientPopulation":null,"diagnosticRequired":null,"brandNameForIndication":""},{"id":"antipyrine-jaw-pain","name":"Jaw Pain","dosing":null,"approvals":[],"diseaseId":"","eligibility":null,"pivotalTrial":null,"restrictions":[],"patientPopulation":null,"diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT04029090","phase":"PHASE1","title":"A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-09-18","conditions":"Healthy Adult Subjects","enrollment":27},{"nctId":"NCT03289208","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-10-27","conditions":"Renal Impairment, Healthy","enrollment":30},{"nctId":"NCT03664544","phase":"PHASE1","title":"PK Study in Subjects With Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-11-06","conditions":"Severe Hepatic Impairment, Healthy","enrollment":12},{"nctId":"NCT00821821","phase":"PHASE2","title":"Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-02","conditions":"Acute Ischemic Stroke (AIS)","enrollment":36},{"nctId":"NCT03346538","phase":"PHASE2","title":"Dose Finding Study of MCI-186 in Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-11-17","conditions":"Acute Ischemic Stroke","enrollment":17},{"nctId":"NCT03289234","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11-16","conditions":"Hepatic Impairment, Healthy","enrollment":22},{"nctId":"NCT00200356","phase":"PHASE4","title":"Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-08","conditions":"Cerebral Infarction","enrollment":401},{"nctId":"NCT04481750","phase":"PHASE1","title":"Study of Oral Edaravone in Healthy Adult Males","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-03-20","conditions":"Healthy Adult Subjects","enrollment":74},{"nctId":"NCT04776135","phase":"PHASE1","title":"Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2021-02-26","conditions":"Healthy Adult Subjects","enrollment":36},{"nctId":"NCT05342597","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-06-10","conditions":"Healthy Adult Subjects","enrollment":16},{"nctId":"NCT04176224","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-17","conditions":"Japanese Patients With ALS","enrollment":9},{"nctId":"NCT04254913","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2020-01-24","conditions":"Japanese Patients With ALS","enrollment":6},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":"Healthy Adult Subjects","enrollment":84},{"nctId":"NCT04493281","phase":"PHASE1","title":"Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-03-22","conditions":"Healthy Adult Subjects","enrollment":42},{"nctId":"NCT01492686","phase":"PHASE3","title":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":137},{"nctId":"NCT00424463","phase":"PHASE3","title":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":181},{"nctId":"NCT00330681","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-05","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":206},{"nctId":"NCT00415519","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":25},{"nctId":"NCT04165824","phase":"PHASE3","title":"Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-11-18","conditions":"ALS","enrollment":185},{"nctId":"NCT05568615","phase":"PHASE3","title":"Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2022-10-26","conditions":"ALS","enrollment":15},{"nctId":"NCT04577404","phase":"PHASE3","title":"Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-10-29","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":124},{"nctId":"NCT05151471","phase":"PHASE3","title":"Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2022-01-11","conditions":"ALS","enrollment":202},{"nctId":"NCT04569084","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-11-13","conditions":"ALS","enrollment":384},{"nctId":"NCT07119021","phase":"PHASE4","title":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","status":"RECRUITING","sponsor":"Ruijun Ji","startDate":"2024-08-01","conditions":"Ischemic Stroke","enrollment":300},{"nctId":"NCT05323812","phase":"PHASE2","title":"ASURE: Alzheimer Study Using oRal Edaravone","status":"COMPLETED","sponsor":"Treeway B.V.","startDate":"2023-03-01","conditions":"Alzheimer Disease","enrollment":61},{"nctId":"NCT05540262","phase":"NA","title":"Edaravone in the Treatment of Optic Neuritis","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2022-01-15","conditions":"Optic Neuritis","enrollment":50},{"nctId":"NCT04370431","phase":"PHASE1","title":"A Study of TTYP01 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2020-04-24","conditions":"Healthy Adult Subjects","enrollment":72},{"nctId":"NCT06107205","phase":"PHASE1","title":"Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-11-07","conditions":"Healthy Adult Subjects","enrollment":29},{"nctId":"NCT02037893","phase":"PHASE2","title":"Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media","status":"COMPLETED","sponsor":"Currax Pharmaceuticals","startDate":"2013-11","conditions":"Acute Otitis Media","enrollment":112},{"nctId":"NCT04984577","phase":"PHASE2","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"SUSPENDED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2021-11-15","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT04259255","phase":"","title":"Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)","status":"UNKNOWN","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-10-21","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":300},{"nctId":"NCT02153541","phase":"PHASE2","title":"Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults","status":"UNKNOWN","sponsor":"Global United Pharmaceutical Corporation","startDate":"2023-04-01","conditions":"Asthma","enrollment":50},{"nctId":"NCT05024526","phase":"NA","title":"Protective Effects of Edaravone Dexborneol","status":"UNKNOWN","sponsor":"Lili Cao","startDate":"2021-04-01","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT04218513","phase":"PHASE1","title":"Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-05-10","conditions":"Drug-drug Interaction","enrollment":24},{"nctId":"NCT03968042","phase":"PHASE2","title":"Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-06-30","conditions":"Alcohol-induced Brain Injury","enrollment":150},{"nctId":"NCT04391361","phase":"PHASE2","title":"The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-11-01","conditions":"Amyotrophic Lateral Sclerosis, Respiratory Function, Scopolamine","enrollment":30},{"nctId":"NCT03272802","phase":"PHASE2, PHASE3","title":"Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2017-03-16","conditions":"Neuromuscular Diseases","enrollment":20},{"nctId":"NCT02430350","phase":"PHASE3","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2015-05","conditions":"Acute Ischemic Stroke","enrollment":1200},{"nctId":"NCT02644915","phase":"NA","title":"Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-03","conditions":"Kidney Transplantation","enrollment":150},{"nctId":"NCT02616458","phase":"NA","title":"The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":"Otitis Media","enrollment":310},{"nctId":"NCT01929096","phase":"PHASE2","title":"Compound Edaravone Injection for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Acute Ischemic Stroke","enrollment":400},{"nctId":"NCT00265239","phase":"PHASE4","title":"Pilot Study of Edaravone to Treat Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2001-04","conditions":"Myocardial Infarction, Reperfusion Injury","enrollment":104},{"nctId":"NCT01894334","phase":"NA","title":"Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-04","conditions":"Acute Aortic Dissection","enrollment":220},{"nctId":"NCT01865201","phase":"PHASE2","title":"Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2009-03","conditions":"Nasopharyngeal Carcinoma, Brain Necrosis","enrollment":154},{"nctId":"NCT01584271","phase":"PHASE2","title":"Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)","status":"UNKNOWN","sponsor":"Assuta Hospital Systems","startDate":"2011-07","conditions":"Acute Otitis Externa","enrollment":75},{"nctId":"NCT01518231","phase":"PHASE1","title":"Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke","status":"UNKNOWN","sponsor":"Zhejiang Hospital","startDate":"2012-01","conditions":"Stroke","enrollment":40},{"nctId":"NCT00153946","phase":"PHASE4","title":"Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Combination Therapy for Acute Ischemic Stroke Study Group","startDate":"2004-08","conditions":"Stroke","enrollment":814}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Sublingual"},"crossReferences":{"chemblId":"CHEMBL277474"},"_approvalHistory":[],"publicationCount":3093,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ANTIPYRINE","genericName":"ANTIPYRINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antipyrine is a small molecule that belongs to the drug class of inhibitors. It is a cyclooxygenase-1 inhibitor, which targets the enzyme prostaglandin G/H synthase 1.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:51:19.949806+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}